Intellia Therapeutics (NTLA)

Download button icon Download

Intellia Therapeutics (NTLA): Signals

No data currently available.

data-ad-format="auto">

Explore Compare Share

TECHNICAL ANALYSIS SUMMARY

Intellia Therapeutics (NTLA)


Indicator:

WEIGHTED MOVING AVERAGE


Last Signal:

BEARISH


Trading: SELL @ $18.36
Signal Strength: STRONG
Recommendation:

Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has the ability to highlight trends across numerous timeframes. This indicator has the ability to smooth historical results to illustrate trend initiation and status. Although this is a simple trend following indicator & can provide good results when coupled with the right indicator. Note, this indicator does not work well in ranging markets producing unwanted whipsaws and false signals.


Intellia Therapeutics (NASDAQ:NTLA) currently has a confirmed downtrend. Recent trading has caused the WMA 15 day average to move below the closing price confirming the short term trend following indicator. Currently, the return on WMA15 is 5.9%.



Weighted moving averages (WMA) are difficult to construct but more reliable than the simple moving averages. WMA permits an unequal weighting on prior time periods.

Calculation: Weighted Moving Average (WMA):
1) Ft= W1At-1 + WnAt-n


PROFILE: Intellia Therapeutics (NTLA)


Stock Exchange: NASDAQ
Company: Intellia Therapeutics
Ticker Codes: | NTLA | NASDAQ:NTLA |

About Intellia Therapeutics (NASDAQ:NTLA):

Intellia Therapeutics, Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; and partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells. Intellia Therapeutics, Inc. has collaboration agreement with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; and Caribou Biosciences, Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Top 10:

Weighted Moving Average

Download button icon Download

No data available.

back to top